Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Inclusion Criteria: * Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI. * Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) * KPS score of at least 70% * Able to swallow oral medications. Exclusion Criteria: * Active CNS metastases and/or carcinomatous meningitis * Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease * Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug. * Has known HIV * History of hepatitis B or known active hepatitis C infection * Has received prior treatment with NKT2152, other HIF2α inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab * Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment * Corrected QT interval calculated by Fridericia formula (QTcF) \> 480 ms within 28 days prior to first dose * Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past * Has a history of interstitial lung disease * Has any active or recent history of a known or suspected autoimmune disease